Kazia Therapeutics gets US RPDD for paxalisib in childhood brain cancer

Kazia Therapeutics, an Australian biotech company, has secured the rare pediatric disease designation (RPDD) for paxalisib (formerly GDC-0084) from the US Food and Drug Administration ... Read More